In Lactobio we focus on new microbial solutions against pathogenic and resistant bacteria.
Lactobio has built a proprietary discovery and screening platform where our team of microbiologists, biotechnologists and biochemists identify, select and grow the best probiotic strains to target microbiome dysfunctions associated with specific diseases.
We develop cosmeceuticals, dietary supplements and live biotherapeutic products.
The products are based on our own research into new, probiotic bacteria strains as well as a PhD collaboration with Bispebjerg Hospital’s dermatological department on skin problems related to Staphylococcus aureus.
The microbiome is the full collection of genes of all the microbes in a community, and the human microbiome is a counterpart to the human genome. The genes in our microbiome outnumber the genes in our genome by about 100 to 1.
About 70-80% of the immune system is localized in the gastrointestinal tract. The functions and overall health is affected by the microbial populations making up the gut microbiota. The intestinal ecosystem communicates with the host via the immune system, and this communication is believed to be important in coding the immune system to prevent chronic diseases such as rheumatoid arthritis, cardiovascular disease, diabetes, allergies etc. Microbiome science gives rise to a new generation of probiotics as solutions to manage dysfunctions of the microbiome.
Probiotics have clinically proven immune supporting effects, resulting in decreased incidence of common infections and colds, as well as inflammatory conditions and gluten and lactose intolerance. Probiotics supports a well-balanced and diverse intestinal environment, with several beneficial effects such as reducing the risk of intestinal infection and provide relief of common intestinal health problems, including irritable bowel syndrome symptoms.
Humans have spent the last 80 years trying to clean “germs” from our homes and bodies. The use of antibiotics to fight infections have saved countless numbers of lives, but with unintended consequences to our microbiomes that we are only beginning to understand.
Antibiotic resistant infections creates a new challenge for public health, and there is no simple solution. Alternative approaches, like probiotics, is needed to treat resistant infections and prevent resistance from spreading.
We work with the gut, oral, skin and vaginal microbiota to create new products targeting specific diseases such as:
- Atopic dermatitis
- Bacterial vaginosis
- Acne vulgaris